



Primary gastric cancer development after *Helicobacter pylori* eradication

Osamu Toyoshima¹, Yutaka Yamaji², Keisuke Hata³

¹Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo, Japan; ²Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo, Japan; ³Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Correspondence to: Osamu Toyoshima. Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo, Japan. Email: t@ichou.com.

Response to: Tahara T, Horiguchi N, Nakagawa Y, *et al.* Gastric atrophy as an important risk factor for gastric cancer development after *Helicobacter pylori* eradication. *Ann Laparosc Endosc Surg* 2017;2:9.

Received: 28 February 2017; Accepted: 26 March 2017; Published: 20 April 2017.

doi: 10.21037/ales.2017.03.20

View this article at: <http://dx.doi.org/10.21037/ales.2017.03.20>

We greatly appreciate the comment (1) on our work (2). In Japan, patients infected with *Helicobacter pylori* (*H. pylori*) undergo eradication therapy funded by the health insurance system (3). Thus, the number of gastric cancers detected after *H. pylori* eradication is rising. It is essential to distinguish gastric cancers detected post-eradication from cancers accompanied by current infection, because the pathophysiology of the upper gastrointestinal tract changes dramatically on *H. pylori* eradication (4). The risk factors for, and clinical features unique to, gastric cancer detected after eradication must be defined, and appropriate treatment strategies urgently developed.

As previously noted, we explored risk factors for primary gastric cancer that developed after *H. pylori* eradication in a large-scale longitudinal cohort characterized by endoscopically revealed gastric atrophy at the time of eradication. We found that the principal risk factor for gastric cancer post-eradication was advanced gastric atrophy, and that the histology of such cancers was intestinal. It has been reported that the mucosa adjacent to the cancer at the time of cancer detection was more atrophic than gastric body mucosa (5). Based on a combination of this report and our report, it is assumed that atrophic mucosa that has not fully recovered after bacterial eradication is a major risk factor for cancer development. Further work is necessary. We agree with the comment made (in another report) that endoscopic detection of gastric cancer after *H. pylori* eradication can sometimes be very difficult; the morphology is challenging (6). We sought to conduct endoscopy as precisely as possible. We used sufficient

sedation, we employed a dye, and we vigorously biopsied small and depressed lesions in seeking to partially overcome the difficulties associated with detection. However, further studies are needed to facilitate early detection of gastric cancer after bacterial eradication. Visibility improves after eradication, sometimes allowing detection of certain lesions that were difficult to see when an *H. pylori* infection was present; infection is associated with mucus on the gastric mucosa, enlarged folds, and/or mucosal edema (7). Therefore, we would recommend that surveillance endoscopy be scheduled for a short period (less than 1 year, if possible) after *H. pylori* eradication, to ensure that missed (but significant) lesions are detected.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Annals of Laparoscopic and Endoscopic Surgery*. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/ales.2017.03.20>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all

aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Tahara T, Horiguchi N, Nakagawa Y, et al. Gastric atrophy as an important risk factor for gastric cancer development after Helicobacter pylori eradication. *Ann Laparosc Endosc Surg* 2017;2:9.
2. Toyoshima O, Yamaji Y, Yoshida S, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. *Surg Endosc* 2016. [Epub ahead of print].
3. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. *J Gastroenterol* 2014;49:1-8.
4. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. *Gastroenterology* 2015;148:719-31.e3.
5. Tahara T, Shibata T, Horiguchi N, et al. A Possible Link between Gastric Mucosal Atrophy and Gastric Cancer after Helicobacter pylori Eradication. *PLoS One* 2016;11:e0163700.
6. Horiguchi N, Tahara T, Kawamura T, et al. Distinct Clinic-Pathological Features of Early Differentiated-Type Gastric Cancers after Helicobacter pylori Eradication. *Gastroenterol Res Pract* 2016;2016:8230815.
7. Mao T, Wang Y, Yin F, et al. Association of Endoscopic Features of Gastric Mucosa with Helicobacter pylori Infection in Chinese Patients. *Gastroenterol Res Pract* 2016;2016:6539639.

doi: 10.21037/ales.2017.03.20

Cite this article as: Toyoshima O, Yamaji Y, Hata K. Primary gastric cancer development after Helicobacter pylori eradication. *Ann Laparosc Endosc Surg* 2017;2:77.